OncoMatch/Clinical Trials/NCT07138755
The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
Is NCT07138755 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Experimental for nsclc.
Treatment: Experimental — To evaluate the Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Required: HER2 (ERBB2) wild-type
Required: MET wild-type
Required: ROS1 wild-type
Disease stage
Required: Stage III
Prior therapy
Cannot have received: systematic anti-tumor treatment
No previous systematic anti-tumor treatment or chest radiotherapy for NSCLC
Cannot have received: chest radiotherapy
No previous systematic anti-tumor treatment or chest radiotherapy for NSCLC
Cannot have received: thoracic radiotherapy
Previously received local treatments for tumor lesions such as thoracic radiotherapy and radiofrequency ablation
Cannot have received: radiofrequency ablation
Previously received local treatments for tumor lesions such as thoracic radiotherapy and radiofrequency ablation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify